Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.72 |
| ▸ | TNF | P01375 | 4/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.62 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779191 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6348648 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6778535 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8072134 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8062483 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL9294255 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8077706 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8076183 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6774095 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6786397 | 1.00 | ADORA2B (0.72) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000066101-A2 | METHOD OF INHIBITING GLYCATION PRODUCT FORMATION | CITY OF HOPE (US) | 2000-11-09 | — | — | WO | claimed |
| US-5288721-A | Substituted epoxyalkyl xanthines | CELL THERAPEUTICS, INC. (US) | 1994-02-22 | — | — | US | claimed |
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2325169-B1 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | Univ Virginia Patent Found (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| EP-2132183-B1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | Univ Virginia Patent Found (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | disclosed |
| EP-0623133-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994022449-A1 | THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| US-5288721-A | Substituted epoxyalkyl xanthines | CELL THERAPEUTICS, INC. (US) | 1994-02-22 | — | — | US | disclosed |
| US-4576947-A | HYDROXYALKYLXANTHINES, INCREASING CEREBRAL BLOOD FLOW, BRONCHODILATORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-18 | — | — | US | disclosed |
| US-4515795-A | INSUFFICIENCY OF CEREBRAL BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | ADORA2B 1559/4885TNF 1497/4885USP2 2663/4885 |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | ADORA2B 2276/4885TNF 2264/4885USP2 1852/4885 |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | ADORA2B 2334/4885TNF 2270/4885USP2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.